Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
In a statement, Wegovy's maker Novo Nordisk said it was "encouraged" by the new guidance from CMS but said it hopes to see Part D coverage expanded for "obesity medicines when used for chronic weight management." The drug maker is among those pushing for Congress to expand coverage of treatments for obesity
TRT Nations approach to treatment incorporates this understanding, recognizing that sustainable weight loss requires addressing hormonal imbalances, metabolic dysfunction, and insulin resistance alongside the weight-reduction effects of tirzepatide
Regular check-ins with your healthcare provider are non-negotiable
Some patients, however, elect to continue the GLP-1 RA because the thought of regaining weight is unacceptable
Retrieved from Khurshid, K
